Home - The YODA Project (original) (raw)
Discovery consists of looking at the same thing as everyone else and thinking something different.
Our Mission
The Yale University Open Data Access (YODA) Project’s mission is to advocate for the responsible sharing of clinical research data, open science, and research transparency. The Project is committed to supporting research focused on improving the health of patients and informing science and public health. The YODA Project can only improve with your feedback. Please share your comments and ideas.
Our Model
The YODA Project seeks mutually beneficial partnerships with Data Partners, promoting independence, responsible conduct of research, good stewardship of data, and the generation of knowledge in the best interest of society. To participate, each Data Partner must transfer full jurisdiction over data access to the YODA Project.
Request Data
Are you ready to request data? To date, 469 trials have been identified as available. The YODA Project and Data Partners continue to identify and add more.
Featured Articles
Articles making use of data shared through the YODA Project. Scroll through featured articles below or learn more about approved data requests.
*141 publications from 117 research projects.
X. Ni, J. Wu, J. Pan et al., Heterogeneity of Radiological Progression Patterns and Association with Outcomes in Patients with
Metastatic Prostate Cancer, Eur Urol Oncol (2023), https://doi.org/10.1016/j.euo.2023.11.019
Butterly EW, Hanlon P, Shah ASV, Hannigan LJ, McIntosh E, Lewsey J, Wild SH, Guthrie B, Mair FS, Kent DM, Dias S, Welton NJ, McAllister DA. Comorbidity and health-related quality of life in people with a chronic medical condition in randomised clinical trials: An individual participant data meta-analysis. PLoS Med. 2023 Jan 17;20(1):e1004154. doi: 10.1371/journal.pmed.1004154. PMID: 36649256; PMCID: PMC9844862.
Lees JS, Hanlon P, Butterly EW, Wild SH, Mair FS, Taylor RS, Guthrie B, Gillies K, Dias S, Welton NJ, McAllister DA. Effect of age, sex, and morbidity count on trial attrition: meta-analysis of individual participant level data from phase 3/4 industry funded clinical trials. BMJ Med. 2022 Sep 1;1(1):e000217. doi: 10.1136/bmjmed-2022-000217. PMID: 36936559; PMCID: PMC9978693.
Wightman H, Quinn TJ, Mair FS, Lewsey J, McAllister DA, Hanlon P. Frailty in randomised controlled trials for dementia or mild cognitive impairment measured via the frailty index: prevalence and prediction of serious adverse events and attrition. Alzheimers Res Ther. 2023 Jun 13;15(1):110. doi: 10.1186/s13195-023-01260-3. PMID: 37312157; PMCID: PMC10262528.
Roy S, Sun Y, Chi KN, Ong M, Malone S, Wallis CJD, Kishan AU, Malone J, Swami U, Gebrael G, Brown JR, Jia AY, Morgan SC, Saad F, Chowdhury S, Agarwal N, Spratt DE. Early Prostate-Specific Antigen Response by 6 Months Is Predictive of Treatment Effect in Metastatic Hormone Sensitive Prostate Cancer: An Exploratory Analysis of TITAN Trial. J Urol. 2024 Jul 26:101097JU0000000000004158. doi: 10.1097/JU.0000000000004158. Epub ahead of print. PMID: 39058790.
Almansour SA, Alqudah MAY, Abuhelwa Z, Al-Shamsi HO, Alhuraiji A, Semreen MH, Bustanji Y, Alzoubi KH, Modi ND, Mckinnon RA, Sorich MJ, Hopkins AM, Abuhelwa AY. Antithrombotic utilization, adverse events, and associations with treatment outcomes in multiple myeloma: pooled analysis of three clinical trials. Ther Adv Med Oncol. 2024 Sep 2;16:17588359241275387. doi: 10.1177/17588359241275387. PMID: 39229471; PMCID: PMC11369879.
Yang H, Qin Y, Li Y, Hu F. Sequential covariate-adjusted randomization via hierarchically minimizing Mahalanobis distance and marginal imbalance. Biometrics. 2024 Mar 27;80(2):ujae047. doi: 10.1093/biomtc/ujae047. PMID: 38801258.
Yang, Haoyu; Qin, Yichen; Wang, Fan; Li, Yang; Hu, Feifang. Balancing covariates in multi-arm trials via adaptive randomization. Comput.Stat.Data Anal. 2023 March; 179:107642. doi: 10.1016/j.csda.2022.107642.
Fukuokaya W, Mori K, Urabe F, Igarashi T, Yanagisawa T, Tsuzuki S, Honda M, Miki K, Kimura T. Bone-Modifying Agents in Patients With High-Risk Metastatic Castration-Sensitive Prostate Cancer Treated With Abiraterone Acetate. JAMA Netw Open. 2024 Mar 4;7(3):e242467. doi: 10.1001/jamanetworkopen.2024.2467. PMID: 38488793; PMCID: PMC10943414.
Roy S, Saad F, Wallis CJD, Sun Y, Spratt DE, Akilla R, Kishan AU, Malone S, Morgan SC. Effect of Concomitant Medications on Treatment Response and Survival in De Novo Metastatic Prostate Cancer: Secondary Analysis of the LATITUDE Study. Eur J Cancer. 2024 Mar;199:113348. doi: 10.1016/j.ejca.2023.113348. Epub 2023 Sep 20. PMID: 38262848.